For Acadia’s Pimavanserin, The Second Time Is The Charm
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in its original Phase III trial.